Insel Gruppe AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- https://www.inselgruppe.ch
Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors
Recruiting
- Conditions
- Intra Cerebral Hemorrhage
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 200
- Registration Number
- NCT06383741
- Locations
- 🇨🇭
Insel Gruppe AG, Inselspital Bern, Bern, Switzerland
Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
Recruiting
- Conditions
- Esophageal Cancer
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 30
- Registration Number
- NCT06361043
- Locations
- 🇨🇭
Inselspital, University of Berne, Deparftment of Radio-Oncology, Berne, Switzerland
CT-guided Lung Biopsy Risk Optimization Method
Not Applicable
Not yet recruiting
- Conditions
- Biopsy, NeedleRisk FactorsRadiology, InterventionalPneumothorax
- Interventions
- Procedure: Fluid application during ct-guided lung biopsy
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 198
- Registration Number
- NCT06340178
- Locations
- 🇨🇭
Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, Bern, Switzerland
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 70
- Registration Number
- NCT06335888
- Locations
- 🇨🇭
Department of Rheumatology and Immunology, University Hospital Bern, Inselspital, Bern, Switzerland
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Recruiting
- Conditions
- Vaccine Immunity in CAR-T Cell Therapy Recipients
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 80
- Registration Number
- NCT06333275
- Locations
- 🇨🇭
University Hospital Bern, Bern, Switzerland
Administration of Intranasal Midazolam for Anxiety in Palliative Care
Phase 2
Recruiting
- Conditions
- AnxietyAcute AnxietyPalliative Care
- Interventions
- Drug: Placebo Nasal Spray 0 mg/spray
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 36
- Registration Number
- NCT06330584
- Locations
- 🇨🇭
Inselspital, Universitätsspital Bern, Bern, Switzerland
🇨🇭Universitäres Zentrum für Palliative Care (UZP), Bern, Switzerland
🇨🇭Zentrum für Palliative Care, Stadtspital Zürich, Zürich, Switzerland
Early Life Intervention in Pediatrics Supported by E-health - SMOKE
Not Applicable
Recruiting
- Conditions
- Asthma in ChildrenBehavior, SmokingLife StyleSmoking ReductionNon-Communicable DiseaseWheezing
- Interventions
- Behavioral: Life-Style appOther: Sham Comparator
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 160
- Registration Number
- NCT06311162
- Locations
- 🇨🇭
Department of Paediatrics, Inselspital, Bern University Hospital, Bern, Switzerland
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Phase 2
Not yet recruiting
- Conditions
- Bile Duct Cancer
- Interventions
- Drug: Gemcitabin, Cisplatin and DurvalumabProcedure: Biliary Radiofrequency AblationProcedure: Endoscopic Retrograde Cholangio-Pancreatography with stenting
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 36
- Registration Number
- NCT06274879
- Locations
- 🇨🇭
Inselspital Bern University Hospital, Bern, Be, Switzerland
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach
Phase 1
Completed
- Conditions
- Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 17
- Registration Number
- NCT06252506
- Locations
- 🇨🇭
Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland
🇨🇭Psychiatric University Hospital Zurich, Zurich, Switzerland
Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy
Recruiting
- Conditions
- Rectal Cancer
- Interventions
- Other: Local excision
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 200
- Registration Number
- NCT06249672
- Locations
- 🇨🇭
Bern University Hospital, Inselspital, Bern, Switzerland
© Copyright 2025. All Rights Reserved by MedPath